vs
Side-by-side financial comparison of QVC Group, Inc. (QVCGA) and Zoetis (ZTS). Click either name above to swap in a different company.
QVC Group, Inc. is the larger business by last-quarter revenue ($2.7B vs $2.4B, roughly 1.1× Zoetis). Zoetis runs the higher net margin — 25.3% vs -1.4%, a 26.6% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -9.1%). Zoetis produced more free cash flow last quarter ($732.0M vs $191.0M). Over the past eight quarters, QVC Group, Inc.'s revenue compounded faster (6.9% CAGR vs 4.4%).
QVC Group, is an American media conglomerate controlled by company chairman John C. Malone, who owns a majority of the voting shares.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
QVCGA vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.7B | $2.4B |
| Net Profit | $-37.0M | $603.0M |
| Gross Margin | 32.9% | 70.2% |
| Operating Margin | 3.7% | 31.9% |
| Net Margin | -1.4% | 25.3% |
| Revenue YoY | -9.1% | 3.0% |
| Net Profit YoY | 97.1% | 3.8% |
| EPS (diluted) | $-17.37 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.7B | $2.4B | ||
| Q3 25 | $2.2B | $2.4B | ||
| Q2 25 | $2.2B | $2.5B | ||
| Q1 25 | $2.1B | $2.2B | ||
| Q4 24 | $2.9B | $2.3B | ||
| Q3 24 | $2.3B | $2.4B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.3B | $2.2B |
| Q4 25 | $-37.0M | $603.0M | ||
| Q3 25 | $-80.0M | $721.0M | ||
| Q2 25 | $-2.2B | $718.0M | ||
| Q1 25 | $-100.0M | $631.0M | ||
| Q4 24 | $-1.3B | $581.0M | ||
| Q3 24 | $-23.0M | $682.0M | ||
| Q2 24 | $20.0M | $624.0M | ||
| Q1 24 | $-1.0M | $599.0M |
| Q4 25 | 32.9% | 70.2% | ||
| Q3 25 | 34.0% | 71.5% | ||
| Q2 25 | 36.4% | 73.6% | ||
| Q1 25 | 34.2% | 72.0% | ||
| Q4 24 | 33.3% | 69.5% | ||
| Q3 24 | 35.3% | 70.6% | ||
| Q2 24 | 36.4% | 71.7% | ||
| Q1 24 | 35.5% | 70.6% |
| Q4 25 | 3.7% | 31.9% | ||
| Q3 25 | 2.7% | 37.0% | ||
| Q2 25 | -101.6% | 36.7% | ||
| Q1 25 | 0.7% | 36.5% | ||
| Q4 24 | -43.2% | 31.6% | ||
| Q3 24 | 6.5% | 36.6% | ||
| Q2 24 | 6.9% | 33.0% | ||
| Q1 24 | 6.2% | 34.1% |
| Q4 25 | -1.4% | 25.3% | ||
| Q3 25 | -3.6% | 30.0% | ||
| Q2 25 | -99.4% | 29.2% | ||
| Q1 25 | -4.8% | 28.4% | ||
| Q4 24 | -43.7% | 25.1% | ||
| Q3 24 | -1.0% | 28.6% | ||
| Q2 24 | 0.8% | 26.4% | ||
| Q1 24 | -0.0% | 27.4% |
| Q4 25 | $-17.37 | $1.37 | ||
| Q3 25 | $-9.89 | $1.63 | ||
| Q2 25 | $-275.46 | $1.61 | ||
| Q1 25 | $-0.25 | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | $-0.06 | $1.50 | ||
| Q2 24 | $2.57 | $1.37 | ||
| Q1 24 | — | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | — |
| Total DebtLower is stronger | $790.0M | — |
| Stockholders' EquityBook value | $-3.1B | $3.3B |
| Total Assets | $7.6B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.8B | $2.1B | ||
| Q2 25 | $897.0M | $1.4B | ||
| Q1 25 | $833.0M | $1.7B | ||
| Q4 24 | $905.0M | $2.0B | ||
| Q3 24 | $873.0M | $1.7B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.1B | $2.0B |
| Q4 25 | $790.0M | — | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $5.0B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $5.1B | — | ||
| Q2 24 | $5.3B | — | ||
| Q1 24 | $5.5B | — |
| Q4 25 | $-3.1B | $3.3B | ||
| Q3 25 | $-3.1B | $5.4B | ||
| Q2 25 | $-3.0B | $5.0B | ||
| Q1 25 | $-981.0M | $4.7B | ||
| Q4 24 | $-971.0M | $4.8B | ||
| Q3 24 | $397.0M | $5.2B | ||
| Q2 24 | $328.0M | $5.0B | ||
| Q1 24 | $255.0M | $5.1B |
| Q4 25 | $7.6B | $15.5B | ||
| Q3 25 | $7.6B | $15.2B | ||
| Q2 25 | $6.7B | $14.5B | ||
| Q1 25 | $9.0B | $14.1B | ||
| Q4 24 | $9.2B | $14.2B | ||
| Q3 24 | $10.8B | $14.4B | ||
| Q2 24 | $10.9B | $14.2B | ||
| Q1 24 | $11.0B | $14.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 12.74× | — | ||
| Q2 24 | 16.28× | — | ||
| Q1 24 | 21.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $244.0M | $893.0M |
| Free Cash FlowOCF − Capex | $191.0M | $732.0M |
| FCF MarginFCF / Revenue | 7.1% | 30.7% |
| Capex IntensityCapex / Revenue | 2.0% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $118.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $244.0M | $893.0M | ||
| Q3 25 | $4.0M | $938.0M | ||
| Q2 25 | $86.0M | $486.0M | ||
| Q1 25 | $-60.0M | $587.0M | ||
| Q4 24 | $212.0M | $905.0M | ||
| Q3 24 | $20.0M | $951.0M | ||
| Q2 24 | $267.0M | $502.0M | ||
| Q1 24 | $26.0M | $595.0M |
| Q4 25 | $191.0M | $732.0M | ||
| Q3 25 | $-27.0M | $805.0M | ||
| Q2 25 | $48.0M | $308.0M | ||
| Q1 25 | $-94.0M | $438.0M | ||
| Q4 24 | $150.0M | $689.0M | ||
| Q3 24 | $-23.0M | $784.0M | ||
| Q2 24 | $213.0M | $370.0M | ||
| Q1 24 | $-14.0M | $455.0M |
| Q4 25 | 7.1% | 30.7% | ||
| Q3 25 | -1.2% | 33.5% | ||
| Q2 25 | 2.1% | 12.5% | ||
| Q1 25 | -4.5% | 19.7% | ||
| Q4 24 | 5.1% | 29.7% | ||
| Q3 24 | -1.0% | 32.8% | ||
| Q2 24 | 8.8% | 15.7% | ||
| Q1 24 | -0.6% | 20.8% |
| Q4 25 | 2.0% | 6.7% | ||
| Q3 25 | 1.4% | 5.5% | ||
| Q2 25 | 1.7% | 7.2% | ||
| Q1 25 | 1.6% | 6.7% | ||
| Q4 24 | 2.1% | 9.3% | ||
| Q3 24 | 1.8% | 7.0% | ||
| Q2 24 | 2.2% | 5.6% | ||
| Q1 24 | 1.7% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | 13.35× | 0.80× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QVCGA
| Other | $915.0M | 34% |
| Home | $754.0M | 28% |
| Beauty | $260.0M | 10% |
| Apparel | $254.0M | 9% |
| Electronics | $187.0M | 7% |
| Accessories | $181.0M | 7% |
| Jewelry | $87.0M | 3% |
| Manufactured Product Other | $38.0M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
